THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Authors :: L. Rigacci
Agostino Antolino
P. L. Zinzani
Samantha Ferrari
L. De Carolis
Monia Capponi
Paolo Falcucci
Alessandro Pulsoni
Eugenio Lucia
A. Ambrosetti
Robert Foa
Francesco Zaja
Natalia Frattarelli
Enrico Tiacci
Edoardo Simonetti
R. Della Seta
Gianluca Gaidano
Giuseppe Visani
Brunangelo Falini
Source :: Hematological Oncology. 37:110-111
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Cancer Research
BRAF inhibitor
business.industry
Hematology
General Medicine
medicine.disease
Oncology
Relapsed refractory
Cancer research
Medicine
Rituximab
Hairy cell leukemia
business
Vemurafenib
medicine.drug

Full Text Access

Tools